Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma - Poll - MDSpire

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

  • By

  • Surbhi Sidana

  • Hitomi Hosoya

  • Alexandria Jensen

  • Lawrence Liu

  • Anmol Goyal

  • Vanna Hovanky

  • Bita Sahaf

  • Sushma Bharadwaj

  • Theresa Latchford

  • Sally Arai

  • Sheryl Leahy

  • Matthew Mei

  • Lihua E. Budde

  • Lori S. Muffly

  • Matthew J. Frank

  • Saurabh Dahiya

  • Myo Htut

  • David Miklos

  • Murali Janakiram

  • October 13, 2023

  • 0 min

Share

Original Source(s)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

  • by Surbhi Sidana, Hitomi Hosoya, Alexandria Jensen, Lawrence Liu, Anmol Goyal, Vanna Hovanky, Bita Sahaf, Sushma Bharadwaj, Theresa Latchford, Sally Arai, Sheryl Leahy, Matthew Mei, Lihua E. Budde, Lori S. Muffly, Matthew J. Frank, Saurabh Dahiya, Myo Htut, David Miklos, Murali Janakiram

  • October 13, 2023

Related Content

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside